1. Introduction {#sec0005}
===============

Coronaviruses are enveloped, positive-sense, single stranded RNA viruses that are distributed broadly among humans which cause respiratory, enteric, hepatic, and neurologic diseases ([@bib0630]). SARS-CoV-2 is the seventh member of the family of corona viruses that infects humans, after MERS-CoV and SARS-CoV-1, it is a beta coronavirus of group 2B with over 70 % similarity in genetic sequence to SARS-CoV-1 ([@bib0270]). Some studies show that angiotensin-convertin enzyme 2 (ACE2) is the receptor for SARS-CoV-2 ([@bib0090]; [@bib0530]). Structural analysis of the spike (S) protein of this new virus showed that its S protein is the one binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells ([@bib0170]). The incubation period is generally 3--7 days (within 14 days) ([@bib0535]), mean incubation period is 5.2 days and 97,5% of patients who develop symptoms do so in the first 11,5 days ([@bib0365]; [@bib0335]). Symptoms of SARS-CoV-2 infection are nonspecific. The most common ones are onset on fever, weakness and dry cough. Less common symptoms are headache, myalgia, fatigue, oppression in the chest, dyspnea, sputum production, diarrhea ([@bib0610]), confusion, sore throat, rhinorrhea, chest pain, nausea and vomiting ([@bib0075]). Up to 50 % of patients develop shortness of breath. Acute respiratory distress syndrome (ARDS) is not an uncommon complication when disease cannot be controlled ([@bib0535]). The percentage of patients requiring ARDS treatment is about 10 % for those who are hospitalized and symptomatic. Some patients are known to be asymptomatic carriers of the infection showing no clinical signs ([@bib0535]). Usually severe patients are older and have chronic diseases, among those the most common associated diseases in severe cases are hypertension and cardiovascular diseases ([@bib0460]). Total white blood count, lymphocytes, and platelets are lower than the average with extended activated thromboplastin time, increased C-reactive protein and muscle enzyme level. Lymphocytes decrease with diseases progression. Secretion of cytokine, such as IL1B, IL1RA, IL6, IL7, IL8, IL-2R, TNF-alfa, known as cytokine storm, is associated with disease severity ([@bib0535]; [@bib0460]; [@bib0175]).

2. Treatment: the pulmonary phase {#sec0010}
=================================

Here we present the drugs used in each phase. Another possible approach is to discuss every drug related to every phase of viral infection (Adhesion, Entry, Endocytosis, Replication, Protein cleavage, Cytokine Storm, Free circulation) as done in a previous study by the author ([@bib0395]).

There are basically three phases of infection, the first one is the *mild infection phase* which only requires symptomatic treatment. Patient shows fever, with or without respiratory symptoms, no hypoxemia and negative imaging. This patient needs testing only if there is a high risk of contagion. It is important to perform a 6-minutes walking test before patient discharge to attest there is no exertional hypoxemia.

*Pulmonary phase* is the second phase which requires mostly antiviral treatment. Patient shows fever, bilateral pulmonary consolidations or hypoxemia. This patient needs to be hospitalized. The currently available options include: Hydroxychloroquine/Azithromycin, Remdesivir, Lopinavir/Ritonavir.

2.1. Hydroxychloroquine {#sec0015}
-----------------------

Hydroxychloroquine alters the process of endocytosis. Hydroxychloroquine is a derivate of chloroquine which alters pH (by increasing it) of endosome and lysosome essential for membrane fusion between host cell and the virus. Due to their basic properties and consequent disruption of cellular vesicle compartments, chloroquine and hydroxychloroquine may also inhibit virion budding and forming of mature virions ([@bib0470]). An in vitro experiment showed that in chloroquine treated cells endosomes vesicles were abnormally enlarged ([@bib0385]). This indicates an altered maturation process of endosomes, blocking endocytosis, resulting in failure of further transport of virions to the replication site ([@bib0385]). Hydroxychloroquine is being tested with azithromycin, and the association has shown some result in viral load reduction, but concern about prolonged QT interval arises with the association ([@bib0215]). Chloroquine and hydroxychloroquine appear to block viral entry into cells not only by inhibition of endosomal acidification, but also by inhibition of glycosylation of host receptors and proteolytic processing, a critical passage of virus-cell ligand recognition. They may also impair the correct maturation and recognition of viral antigens by antigen-presenting cells (APCs) that require endosomal acidification for antigen processing ([@bib0470]). This could be the explanation as to why they also have immunomodulatory effect through attenuation of cytokine production and inhibition of autophagy and lysosomal activity in host cells ([@bib0680]; [@bib0160]). Hydroxychloroquine inhibits IL-6, IL-1beta and TNF-alfa release ([@bib0470]), and it showed also anti-thrombotic properties interfering with platelet aggregation and blood clotting proteins ([@bib0470]). An open-label nonrandomized study of 36 patients reported improved virologic clearance with hydroxychloroquine. They also reported that the addition of azithromycin to hydroxychloroquine resulted in superior viral clearance in some patients ([@bib0215], [@bib0220]). Azithromycin has been shown to be active in vitro against Zika and Ebola viruses ([@bib0215]; [@bib0495]; [@bib0390]), and to prevent severe respiratory tract infections when administrated to patients suffering from viral infections ([@bib0015]). Another prospective randomized study of 30 patients showed no benefit and no difference in virologic outcomes between the treated patients versus non treated patients ([@bib0080]). Given the role of iron in several human viral infections, a potential involvement of Hydroxychloroquine in iron homeostasis in SARS-CoV-2 infection has been suggested ([@bib0470]). Chloroquine and hydroxychloroquine are given orally and are generally well tolerated, however they can cause rare and serious effects such as QTc prolongation, hypoglycemia, neuropsychiatric effects and retinopathy. Known major drug-drug interactions happen with drugs who are also substrates of CYP2D6 and CYP3A4 ([@bib0515]). A randomized clinical trial of 62 patients from China suffering from COVID-19 showed how hydroxychloroquine shortens time to clinical recovery and absorption of pneumonia (ChiCTR2000029559) ([@bib0085]). One study (NCT04261517, Phase 3) ([@bib0120]) showed positive preliminary outcomes, even though the sample was small.

2.2. Remdesivir {#sec0020}
---------------

Targeting the RNA-dependent RNA polymerase (RdRp) showed low specificity and low potency, nevertheless the most promising drug belonging to this class is Remdesivir ([@bib0355]; [@bib0240]). Remdesivir is one of the most promising antiviral in fighting SARS-CoV-2. It is an adenosine nucleotide analogue prodrug with broad-spectrum activity against pneumoviruses, filoviruses, paramyxoviruses and coronaviruses ([@bib0540]). It can inhibit the replication of multiple coronaviruses in respiratory epithelial cells. A recent study showed Remdesivir can compete with natural counterpart ATP. Once it is added to the growing chain, it does not cause an immediate stop but it stops the strand after 3 more nucleotides are added [@bib0240]). Remdesivir is currently being tested for antiviral activity against the Ebola virus ([@bib0425]). Coronaviruses are equipped with exonuclease proofreading enzyme, that makes nucleotide analogues generally a poor therapeutic choice, surprisingly Remdesivir was effective against SARS-CoV-1 and MERS-CoV ([@bib0540]). Tissue culture studies have shown that Remdesivir is also active against a wide number of highly different coronaviruses including human CoVs, showing a broad-sprectrum anti-CoV activity ([@bib0045]). Mouse models of SARS-CoV-1 pathogenesis show that early therapy and administration of Remdesivir significantly reduced the presence of the virus in the lungs. Treated animals showed improved clinical signs of disease compared to untreated control animals ([@bib0540]). Therapeutic and prophylactic use of Remdesivir has recently been tested in nonhuman primate model of MERS-CoV infection. Administration of the drug 24 h prior to inoculation prevented the virus from inducing clinical disease and prevented replication in respiratory tissue, thus preventing lung lesions to form. Therapeutic usage of Remdesivir (12 h after inoculation) showed similar results ([@bib0150]). SARS-CoV-2 RdRp is composed of the nonstructural proteins nsp8 and nsp12. Enzyme kinetics recently showed that this RdRp efficiently incorporates the active triphosphate form of Remdesivir into RNA ([@bib0245]). Since human safety data are showing promising results ([@bib0425]), human clinical trials are ongoing. Remdesivir is usually well tolerated, uncommon adverse effects are elevated transaminases and kidney injury; no significant interactions occur with CYP enzymes ([@bib0515]). Intravenous infusion phase 1 clinical trials are showing good safety and pharmacokinetics properties ([@bib0515]). The National Institute of Health is sponsoring a randomized double-blind clinical trial comparing Remdesivir with standard of care (NCT04280705, Phase 3) ([@bib0120]). Hospitalized patients with advanced COVID-19 and lung involvement who received Remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from this randomized, controlled trial involving 1063 patients. Results are quite controversial between different studies. An example of that is another trial (NCT04257656, Phase 3) of 237 patients, that showed no statistical significant benefits with Remdesivir ([@bib0615]).

2.3. Lopinavir/Ritonavir {#sec0025}
------------------------

The Main protease is another suitable drug target, one example in doing so is the combination of Lopinavir/Ritonavir ([@bib0355]). Lopinavir/ritonavir is a medication for the human immunodeficiency virus (HIV) used in combination with other medications to treat adults and children who are infected with HIV-1. Lopinavir in particular is an HIV-1 protease inhibitor, its combination with ritonavir has shown to be effective against SARS-CoV-1 in patients and in tissue culture, via inhibition of 3-chymotripsin-like protease (3CLpro), the main protease ([@bib0105]; [@bib0145]). The combination of the two also reduced clinical scores and disease progression in animals infected with MERS-CoV ([@bib0070]). Previous studies showed the combination of lopinavir and ritonavir to be of some use for SARS-CoV-1 and MERS-CoV infected patients ([@bib0655]). Clinical studies in SARS-CoV-1 were associated with reduced mortality and intubation rates ([@bib0655]; [@bib0060]). Both anti-HIV drugs interacted well with the residues at the active site of SARS-CoV-2 3CLpro. Ritonavir showed a somewhat higher number atomic contacts, a somewhat higher binding efficiency, and higher number of key binding residues compared to lopinavir, which correspond with the slightly lower water accessibility at the 3CLpro active site ([@bib0435]). Adverse effects of Lopinavir/ritonavir include gastrointestinal distress such as nausea and diarrhea, and hepatotoxicity ([@bib0515]). Major drug-drug interactions occur with CYP3A4, CYP2D6, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and P-glicoprotein ([@bib0515]). Cao and colleagues reported the results of an open-label randomized clinical trial (ChiCTR2000029308) comparing the efficacy of lopinavir/ritonavir versus standard care in 199 patients with COVID-19. Time to clinical improvement was similar in both groups, no significant differences in viral clearance and in mortality rates were observed ([@bib0055]).

3. Treatment: the inflammatory phase {#sec0030}
====================================

*The inflammatory phase* is the third phase, which leads to the most common complication of COVID-19 which is ARDS. Patient shows fever, severe hypoxemia with partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio \<300 and multiple pulmonary consolidations.

Therapeutic choices include: Tocilizumab and analogues like Sarilumab, Anakinra, Baricitinib, Eculizumab, Emapalumab and Heparin.

3.1. Is Tocilizumab a reasonable choice? Fighting the cytokine storm {#sec0035}
--------------------------------------------------------------------

SARS-CoV-1, MERS-CoV and SARS-CoV-2 show a relatively higher mortality rates then other coronaviruses and are associated with a cytokine storm, this might suggest that inflammatory responses might play a role in the pathogenesis. If that is the case, targeting the coronavirus alone with antiviral therapy might not be enough to reverse highly pathogenic infections. These observations led to explore the usage of therapies that included type I and II interferons. Interferon beta displayed the best efficacy in reducing MERS-CoV replication in tissue culture ([@bib0065]; [@bib0260]). A randomized control trial is ongoing in South Arabia (MIRACLE Trial) to determine whether the combination of Lopinavir/Ritonavir and Interferon beta could improve clinical outcomes in MERS-CoV infections ([@bib0010]). In a humanized transgenic mouse MERS-CoV infection model, remdesivir showed more activity and efficacy in prophylactic and therapeutic use then the combination of Lopinavir/Ritonavir and Interferon beta ([@bib0545]). Triple combination of interferon beta-1b, lopinavir/ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 is being tested in an open-label, randomized, phase 2 trial (NCT04276688). Early triple antiviral therapy was safe and superior to lopinavir/ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay ([@bib0275]).

3.2. Tocilizumab and other IL-6 receptor inhibitors {#sec0040}
---------------------------------------------------

High levels of interleukin 6 (IL-6) and Interleukin 8 (IL-8) were found in the acute stage associated with lung lesions in SARS-CoV-1 patients. Especially IL-6 can induce the hyper-inflammatory response due to the SARS-CoV-1 invasion of the respiratory tract ([@bib0605]). Interestingly, in human epithelial cells, SARS-CoV-1 was able to induce greater IL-6 when compared to influenza A virus ([@bib0440]). Although in some murine viral infections IL-6 plays a protective and essential role in the resolution process, in others like in SARS-CoV-1 high levels of IL-6 were associated with severe inflammation and correlated with mortality in the mice ([@bib0430]; [@bib0135]). This happens also with SARS-CoV-2 in COVID-19 patients: some retrospective and meta-analysis studies show how elevated IL-6 and C-reactive protein (CRP) correlate with mortality and severe disease in comparison to moderate disease ([@bib0685]; [@bib0235]; [@bib0110]; [@bib0225]). More evidence suggests that critically ill patients with severe respiratory failure and SARS-CoV-2 have either immune dysregulation or macrophage-activation syndrome, both of which are characterized by pro-inflammatory cytokines. The immune dysregulation, in particular, is driven by the Interleukin-6 (IL-6) and not by Interleukin-1beta (IL-1beta) [@bib0225]). Interestingly, among all SARS-CoV-1 structural proteins (N, S, E and M), the nucleocapsid protein (N) significantly induced the activation of IL-6 promotor in human airway epithelial cell cultures ([@bib0665]). IL-6 gene expression is activated by the N protein which binds to the NF-kB regulatory element on IL-6 promoter and facilitates its translocation from cytosol to nucleus. The N protein is essential for IL-6 secretion to happen, since deletion of the C-terminus of the N protein resulted in the loss of function in the activation of IL-6 ([@bib0665]). This again points towards excessive activation of the innate immune response. Another proof of that is the damage shown to the pulmonary interstitial arteriolar walls that is more associated with the inflammatory response rather than the pathogenic effect of CoVs ([@bib0370]). Since high levels of IL-6 are associated with SARS-CoV-1 and SARS-CoV-2 infections as shown above and since high serum levels of IL-6 have been associated with lung lesions in SARS-CoV-2 patients in the acute and later stages ([@bib0605]; [@bib0685]; [@bib0235]; [@bib0110]; [@bib0225]; [@bib0265]), a valid option could be targeting the expression of IL-6 with Tocilizumab a monoclonal antibody against IL-6 Receptor: this option is currently being tested in some patients in Italy with extreme lung injuries (NCT04317092) ([@bib0120]). This option should be approached only when there are radiological and clinical signs of progression of the lung lesions. Common side effects of Tocilizumab include increase in upper respiratory tract infections, headache, hypertension, hepatotoxicity, infusion related reactions. Major effects include hematologic effects, infections, gastrointestinal perforations and hypersensitivity reactions. Interactions with several CYP450 isoenzymes are described ([@bib0515]). Interestingly, Tocilizumab targets both IL-6 receptor (IL-6R) forms: the soluble one (sIL-6R) and the membrane bound one (mIL-6R). Those two forms seem to work in very divergent ways, since the soluble one is believed to be pro-inflammatory, and the membrane bound IL-6 Receptor is believed to act in an anti-inflammatory way ([@bib0500]), inhibiting only the pro-inflammatory one could then be a better option then targeting them both, as suggested in a previous work by the author ([@bib0400]). Sarilumab, another antibody against IL-6 receptor used in rheumatoid arthritis ([@bib0330]), is being tested in a multicenter, double-blind, clinical phase 2/3 in patients with severe COVID-19 (NCT04315298) ([@bib0515]). Other drugs that showed potential inhibition of IL-6 related JAK/STAT pathway are: Fingolimod which showed to inhibit proliferation and epithelial-mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signaling ([@bib0620]), a clinical trial in COVID-19 patients is ongoing (NCT04280588, Phase2) ([@bib0120]); glatiramer acetate showed potential to downregulate both IL-17 and IL-6 in the central nervous system in an autoimmune encephalitis model ([@bib0020]).

3.3. Canakinumab, Anakinra and Emapalumab {#sec0045}
-----------------------------------------

Another option in fighting the cytokine storm is targeting IL-1 with Canakinumab, a monoclonal antibody against IL-1-beta, which is being approved by the Italian drug agency (AIFA) in COVID-19 pneumonia. It is used for the treatment of familial Mediterranean fever and it has been shown to be of use in atherosclerotic diseases for its anti-inflammatory properties ([@bib0445]; [@bib0505]). A clinical phase 2 trial is ongoing in patients with COVID-19 pneumonia with Canakinumab (NCT04362813) ([@bib0120]).

Anakinra is also another option in targeting IL-1 Receptor, which is used for rheumatoid arthritis ([@bib0475]). Anakinra is being tested with Tocilizumab in a phase 2 clinical trial (NCT04339712) ([@bib0120]). It is also being tested in COVID-19 patients combined with Emapalumab (NCT04324021, Phase2/3 multicenter randomized clinical trial) ([@bib0120]). Emapalumab is a human monoclonal antibody against interferon gamma which acts blocking its binding to cell surface receptors and activation of inflammatory signals, it is used to treat the severe inflammatory condition of hemophagocytic lymphohistiocytosis (HLH) ([@bib0005]).

3.4. Gimsilumab {#sec0050}
---------------

After the SARS-CoV-2 infection, CD4 + T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate Granulocyte-macrophage colony-stimulating factor (GM-CSF). The cytokines environment induces inflammatory CD14^+^ CD16^+^ monocytes with high expression of IL-6 and accelerates the inflammation ([@bib0690]). Since IL-6 is not the only responsible of the inflammation, targeting GM-CSF is another possible therapy which has led to the developing and use of anti-GM-CSF antibodies like Gimsilumab. Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis ([@bib0315]; [@bib0525]). It is being tested for lung injury or Acute Respiratory Distress Syndrome due to COVID-19, in a phase 2 clinical trial (NCT04351243) ([@bib0120]).

3.5. Coagulation disorder: is heparin the answer? {#sec0055}
-------------------------------------------------

Is the hyper-inflammatory state the only cause of acute lung injuries? Some studies are starting to show the presence of an associated coagulopathy and, in some cases, antiphospholipid antibodies in patients with COVID-19 who showed multiple infarcts. These patients had evidence of ischemia in the lower limbs, in the hands and bilateral cerebral infarcts in multiple vascular territories ([@bib0670]). These results show a systemic coagulation disorder, but it is possible that the coagulopathy starts in the lungs, and only after it spreads into the other organs. This might suggest that death occurs not only because of the inflammatory response but also because of the local coagulation disorder. Coagulopathy in SARS-CoV-2 infection has been shown to be associated with high mortality, with elevated D-dimer levels and elevated fibrinogen degradation products (FDP) being particularly important markers for the coagulopathy. A comparative analysis between survivors and non-survivors pneumonia patients revealed significantly higher D-dimers, FDP levels, longer PT and APTT compared to survivors on admission; more than 70 % of non survivors met the criteria of disseminated intravascular coagulation (DIC) during hospitalization ([@bib0565]). It has also become clear that COVID-19-related DIC is not a bleeding diathesis but rather a predominantly prothrombotic DIC with high venous thromboembolism rates, elevated D-dimer and fibrinogen levels, low anti-thrombin levels. The use of anticoagulant therapy with heparin showed to decrease mortality ([@bib0570]). This was especially so in patients who meet the sepsis induced coagulopathy (SIC) criteria (a score \> = 4 is required) and in patients with markedly elevated D-dimer ([@bib0570]). This suggest that Low molecular weight heparin (LMWH) at prophylactic dose should be considered in patients meeting SIC criteria and elevated D-dimer. Heparin showed, besides its primary known use, to have also anti-inflammatory properties ([@bib0455]; [@bib0660]; [@bib0350]), that could be of therapeutic value in those patients with severe lung inflammation and impaired pulmonary exchange. ARDS is a common complication of COVID-19. Activation of coagulation system has been linked to ARDS onset. It has been shown that the median plasma concentrations of tissue factor and plasminogen activator inhibitor-1 were significantly higher at day seven in patients with ARDS, as compared to non-ARDS ([@bib0450]). Coagulopathy arises from thrombin generation mediated by localized tissue factor, and depression of fibrinolysis mediated by plasminogen activator in the lungs, in accordance with an increase in plasminogen activator inhibitor-1 (PAI-1) ([@bib0450]; [@bib0230]). This again points towards how heparin might be helpful in fighting this coagulopathy. Another interesting therapeutic property of heparin is its supposed antiviral role ([@bib0550]). Heparin showed to inhibit infection in experimental vero cells injected with sputum from a patient with SARS-CoV-1 pneumonia ([@bib0595]). Recently, Cui and colleagues, reported the prevalence of venous thromboembolism (VTE) in 81 severe COVID-19 patients with pneumonia admitted in the intensive care unit. The incidence in these patients of VTE (not under thromboprophylaxis) was 25 % and eventually 40 % of them died ([@bib0125]). Increased levels of D-Dimer predicted VTE with a sensitivity of 85 %, specificity of 88.5 % and negative predictive value of 94 % ([@bib0125]). The prevalence of VTE in ICU patients with COVID-19 pneumonia reported by Cui is higher than the prevalence of VTE associated with other diseases: in a meta-analysis of seven studies including 1783 ICU patients, the mean rate of VTE diagnosis was 12.7, thus suggesting a direct role of COVID-19 in VTE pathogenesis ([@bib0405]). Moreover, coagulopathy is known to happen in the majority of patients who die of COVID-19 ([@bib0565]). This suggests that severe COVID-19 patients are at high VTE risk and mortality risk and anticoagulant therapy might improve their prognosis ([@bib0320]). Many mechanisms might contribute to increased VTE risks in COVID-19 patients including: endothelial damage, microvascular thrombosis and occlusion, or even autoimmune mechanism ([@bib0670]). Interestingly, in a recent study of 83 patients, despite the evidence of a progressive COVID-19 coagulopathy over time in some patients, none of those maintained on prophylactic Low-molecular-weight heparin (LMWH) developed systemic DIC. The authors propose also the existence of a pulmonary specific vasculopathy and notice how the ACE2 receptor utilized by SARS-CoV-2 is expressed on both type II pneumocytes and vascular endothelial cells within the lungs, suggesting a possible direct infection and/or damage of those cells by SARS-CoV-2 ([@bib0210]). Moreover, the cytokine storm associated with COVID-19 could very well be responsible for the thrombin generation and fibrin deposition within the lungs. Interestingly, a recent study showed markedly hypercoagulable thromboelastometry profiles in COVID-19 patients, thus showing how patients with acute respiratory failure may present a severe hypercoagulability rather than a consumptive coagulopathy ([@bib0555]). Recent statements by the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis or full therapeutic-intensity anticoagulation ([@bib0575]; [@bib0115]). A Randomized, Open-label Phase 3 Clinical Trial is ongoing to study prevention of COVID-19-associated thrombosis, coagulopathy and mortality with Low- and High-dose anticoagulation with Enoxaparin (NCT04345848) ([@bib0120]).

3.6. Coagulation system and immune system: cross-talking {#sec0060}
--------------------------------------------------------

The activation of both the immune system and the coagulation system is not simply associated in time, but there is extensive crosstalk between the two systems ([@bib0095]). Upon injury by a micro-organism, immune cells are recruited and many pro-inflammatory cytokines are secreted, and these cytokines are key mediators of activation of coagulation ([@bib0035]). Moreover, inflammation not only leads to activation of coagulation, but coagulation also affects inflammatory activity ([@bib0095]). Acute infections can alter hemodynamics, clotting and fibrinolytic systems leading to ischemic events ([@bib0375]). This is what might happen with SARS-CoV-2 infection too. High levels of IL-6 and IL-8 have been associated to SARS-CoV-1 and SARS-CoV-2 as already mentioned above, and high levels of these cytokines also correlate with mortality. There is also a clear connection that has been proven between inflammatory events and the development of thrombovascular disease in many clinical scenarios ([@bib0580]). Complications like venous thromboembolism (VTE) has been connected to inflammation and some results showed that patients with VTE have higher plasma levels of interleukin-8 (IL-8) then those without VTE ([@bib0580]; [@bib0490]). Both IL-6 and IL-8 have a role in activation of coagulation, and higher levels of these cytokines may correlate with higher rate of VTE events ([@bib0580]; [@bib0490]), this also might happen in the lungs in patients with severe COVID-19 pneumonia. It has been reported how IL-8 production directly correlates with thrombin-antithrombin (TAT) complex ([@bib0285]). Abnormal clot lysis was observed in the presence of IL-1 beta, IL-6 and IL-8, using thromboelastography. Interestingly, IL-8 shows the most significant results in thromboelastography (TEG) analysis making the clot form faster (hypercoagulation), with an increase in cross-linking fibrin fibers. IL-8 showed also to be able to alter erythrocyte structure and its addition produced a clot with an increased time to clot formation that is less stable and more prone to early lysis ([@bib0035]). Thus, the clotting process with increased levels of IL-8 might result in the presence of small thrombi, with an increased risk for vessels occlusion as observed in some COVID-19 patients autopsies ([@bib0635]). Inflammation stimulates coagulation by leading to intravascular tissue factor expression and down regulation of the fibrinolytic pathway ([@bib0195]). Interestingly, IL-6 is responsible for one of the main mechanism whereby inflammation activates coagulation by inducing tissue factor (TF) expression ([@bib0095]; [@bib0340], [@bib0345]). Moreover IL-6 can increase the expression of fibrinogen, factor VIII and vWF, activation of endothelial cells and increase platelets production and reduce the levels of inhibitors of haemostasis such as antithrombin and protein S ([@bib0305]). It has been reported how IL-6 can also elicit a dose-dependent acceleration of thrombus development in arterioles of a WT mice ([@bib0520]). IL-6 can also cause the clot to form faster and in a less stable form, and causes a more hypercoagulable clot then IL-1 beta; but IL-8 is still the most potent procoagulant cytokine between those three: causing the most significant changes at all levels of coagulation, including fibrin, thrombin and cellular interactions ([@bib0030]). IL-8 promotes procoagulant activity, also by triggering platelet activation ([@bib0485]). This is evidence of how cytokines and inflammation activate coagulation.

Moreover, activation of coagulation in healthy human subjects by the administration of recombinant factor VIIa also elicits a small but significant increase in the concentrations of IL-6 and IL-8 in plasma ([@bib0140]). Thrombin too has been shown to have many non-coagulant effects, among these there is IL-6 induction in fibroblasts, epithelial cells and mononuclear cells in vitro ([@bib0290]) and induction of IL-8 production in endothelial cells ([@bib0295]). This is evidence of a well-known cross-talking between inflammations and coagulation, and of a possible loop mechanism which could be amplified in a setting like that of COVID-19.

3.7. Baricitinib {#sec0065}
----------------

Targeting the *endocytosis* process is also possible with other drugs other than hydroxychloroquine. One known regulator of endocytosis is the AP2-associated protein kinase 1(AAK1). Using Artificial Intelligence it was possible to find a good inhibitor of AAK1 like Baricitinib, a known Janus kinase inhibitor which can reduce both viral entry and inflammation. It is a selective and powerful JAK-STAT signaling inhibitor thus being effective against the consequences of the elevated levels of cytokines, not only being able of lowering IL-6 levels ([@bib0100]), but it also has the potential to inhibit clathrin-mediated endocytosis and thereby inhibit viral infection of cells. It targets members of the numb-associated kinase (NAK) family (AAK1 and GAK), the inhibition of which has been shown to reduce viral infection in vitro ([@bib0025]). It can be administered orally and has acceptable side effect profile, besides having little interaction with CYP enzymes and drug transporters ([@bib0560]), since renal elimination is the main clearance mechanism for Baricitinib ([@bib0325]). It regulates innate immunity blocking type-I IFN signal. Baricitinib downregulates CD80/CD86 expression, but not that of HLA-DR in human monocyte-derived dendritic cells in a concentration-dependent manner. Moreover, assessment of the action of Baricitinib on plasmacytoid dendritic cells (pDC), which are the main source of type-I IFN, showed suppressed production of type-I IFN ([@bib0325]). This makes Baricinitib a valid option in every phase of the viral infection, the early stages to reduce viral entry in the cells, and later stages for its anti-inflammatory properties. A Phase2/3 clinical trial is ongoing (NCT04340232) ([@bib0120]).

3.8. Ruxolitinib {#sec0070}
----------------

Since high levels of IL-6 are the results of excessive inflammatory response, one way to target IL-6 is with antibodies like Tocilizumab, another way is to counteract the response induced by IL-6. This can be done by inhibiting the JAK 1/2 pathway with drugs like Ruxolitinib. Ruxolitinib is a small drug belonging to the class of Janus kinase (JAK) inhibitors and currently clinically used in the treatment of JAK2 mutated myeloproliferative neoplasms, including myelofibrosis and polycythemia vera ([@bib0590]; [@bib0585]). It shows activity against the JAK2 isoform and also the JAK1 isoform, which play a major role in the signaling pathway of inflammatory cytokines ([@bib0420]). JAK3 seems to be less sensitive to ruxolitinib ([@bib0465]), it also shows anti-inflammatory activity which may be beneficial in its clinical use ([@bib0040]); it is also implicated in the suppression of the harmful consequences of macrophage activation hemophagocytic lymphohistiocytosis ([@bib0410]), which is an under-recognized hyperinflammatory syndrome characterized by fulminant and fatal hypercytokinemia with multi organ failure ([@bib0415]). It has been proven that the expression of major inflammatory cytokines such as TNF alfa and IL-6 was highly reduced in inflammatory human macrophages exposed to ruxolitinib ([@bib0040]). It has also been shown through an analysis of mRNA expression of cytokines by PCR array that the major inflammatory cytokines, IL-6 and TNF alfa, were highly reduced and down-regulated by Ruxolitinib at both protein and mRNA level ([@bib0205]). Ruxolitinib has many effects on many types of cells like Natural Killers (NKs), Dendritic Cells (DCs), and T cells. NKs are usually reduced after Ruxolitinib administration, this happens after NKs maturation is impaired. Ruxolitinib profoundly impairs DCs migration; subsequently, the loss of trafficking DCs may lead to reduced activation of T cells in draining lymph nodes ([@bib0185]). Also Treg cells are negatively regulated with Ruxolitinib ([@bib0185]). All these results point towards a possible use of Ruxolitinib as an IL-6 inhibitor like Tocilizumab in the advanced stages of COVID-19, a trial is ongoing(NCT04334044, Phase1/2) ([@bib0120]).

[Table 1](#tbl0005){ref-type="table"} summarizes the main therapeutic options that have been discussed here ([Table 1](#tbl0005){ref-type="table"}).Table 1Summarizes main drugs against SARS-CoV-2 and clinical trials.Table 1DrugMechanism of actionTrial/PhaseHydroxychloroquine ([@bib0470]; [@bib0215]; [@bib0160]; [@bib0495]; [@bib0015]; [@bib0085]; [@bib0120])Inhibition of endosomal acidification, inhibition of glycosylation of host receptors and proteolytic processing ([@bib0470]). Immunomodulatory effect ([@bib0470]; [@bib0160]). Iron homeostasis alteration ([@bib0470]).NCT04261517, Phase 3 (+)ChiCTR2000029559 (+)Remdesivir ([@bib0355]; [@bib0240]; [@bib0540]; [@bib0045]; [@bib0150]; [@bib0245]; [@bib0120]; [@bib0615])RNA-dependent RNA polymerase inhibitionNCT04280705,Phase 3 (+)NCT04257656, Phase 3(-)Lopinavir/Ritonavir ([@bib0355]; [@bib0105]; [@bib0145]; [@bib0070]; [@bib0655]; [@bib0435]; [@bib0055])Main protease inhibitorChiCTR2000029308(-)NCT04276688(triple combination of interferon beta-1b, lopinavir--ritonavir, and ribavirin was superior to lopinavir/ritonavir alone)Tocilizumab ([@bib0515]; [@bib0120]; [@bib0685]; [@bib0235]; [@bib0110]; [@bib0225])IL-6 Receptor InhibitorNCT04317092, Phase 2Sarilumab ([@bib0330]; [@bib0515])IL-6 Receptor InhibitorNCT04280588, Phase2Fingolimod ([@bib0620]; [@bib0120])inactivating IL-6/STAT3 pathwayNCT04280588, Phase2Canakinumab ([@bib0445]; [@bib0505]; [@bib0120])monoclonal antibody against IL-1-betaNCT04362813, Phase2Anakinra ([@bib0120]; [@bib0475])monoclonal antibody against IL-1 ReceptorNCT04339712,Phase 2NCT04324021, Phase2/3 (with Emapalumab)Gimsilumab ([@bib0690]; [@bib0315]; [@bib0525]; [@bib0120])monoclonal antibody against GM-CSFNCT04351243, Phase 2Heparin ([@bib0565], [@bib0570]; [@bib0455]; [@bib0660]; [@bib0350]; [@bib0210]; [@bib0120])anticoagulant, anti-inflammatory ([@bib0455]; [@bib0660]; [@bib0350])NCT04345848,antiviral ([@bib0550]; [@bib0595])Phase 3Baricitinib ([@bib0100]; [@bib0025]; [@bib0325]; [@bib0120])JAK-STAT signaling inhibitor ([@bib0100])NCT04340232,Inhibition of clathrin-mediated endocytosis ([@bib0025])Phase 2/3Ruxolitinib ([@bib0590]; [@bib0585]; [@bib0420]; [@bib0185]; [@bib0120])Janus kinase (JAK) inhibitorNCT04334044, Phase1/2

4. Other possible drugs {#sec0075}
=======================

The author discussed the most valid options against COVID-19, but many new alternatives arise every day. Future possible treatments are discussed here. Inhibiting the receptor ACE2 seemed like a reasonable strategy but at the moment is controversial and has shown many possible side effects ([@bib0255]). Another interestingly choice is to use a recombinant form of the ACE2 receptor to "keep the virus busy" and thus reduce the infected number of cells by inhibiting the first phase of infection, this has particularly been tested in patients with ARDS in the past ([@bib0310]). Another option is targeting *viral entry*: cleavage and activation of SARS-CoV-1 spike protein (S) by a host cell protease is essential for viral entry, this host cell protease is called TMPRSS2. Potential in vitro proven inhibitors are camostat mesylate ([@bib0300]) and K11777 ([@bib0675]), a clinical trial is ongoing for camostat mesylate in COVID-19 patients (NCT04321096 Phase1/2) ([@bib0120]). Targeting the RNA-dependent RNA polymerase (RDRp) can be done with Favipiravir a drug belonging to the same class as Remdesivir ([@bib0175]), a clinical trial is ongoing to study Favipiravir against standard of care (NCT04358549, Phase 2) ([@bib0120]). Targeting the Main protease proteins is what Lopinavir/Ritonavir does ([@bib0355]), another recently discovered in vitro protease inhibitor is compound 13-b, which is a modified alfa-ketoamide ([@bib0380]).

Coagulopathy and inflammatory response are intertwined as already discussed. Both the presence of coagulation disfunction and the excessive activation of inflammatory response point towards and excessive activation of the complement system. In a murine model lacking C3 and thus unable to activate the common complement pathway, SARS-CoV-1 infection severity was reduced ([@bib0250]). In a murine model of MERS-CoV infection, increased concentrations of C5a and C5b were found in the serum and in lung tissues ([@bib0280]). This suggests a possible use of Eculizumab, a C5 complement inhibitor, to both prevent coagulation disorder and hyper-inflammation activation (NCT04288713) ([@bib0120]).

Targeting viral components such as the spike proteins of the virus with specific antibodies is another therapeutic option which is currently being tested ([@bib0625]). Neutralizing Antibodies are active during the free circulation of the virus. Coronaviruses neutralizing antibodies usually target the spike proteins(S) on the viral surface of the virus which allow it to enter host cells. The S protein has two subunits: one that mediates cell binding, S1 consisting of 4 domains, and one that mediates cell fusion, the S2 domain. The most neutralizing antibodies are shown to target the receptor interaction site in S1 subunit ([@bib0130]; [@bib0155]; [@bib0165]; [@bib0180]; [@bib0190]; [@bib0200]; [@bib0640]). As shown in previous studies spike proteins of SARS-CoV-2 and SARS-CoV-1 are 77.5 % identical by primary amino acid sequence and structurally very similar ([@bib0645]; [@bib0600]), they bind the ACE2 protein ([@bib0360]) through the S1 subunit(S1B). The latest developed antibodies showing neutralizing properties is the Human 47D11 antibody, which was shown to target the S1B receptor binding domain of SARS-CoV-1 and SARS-CoV-2. Despite its capacity to inhibit infected cells with SARS-CoV-1 and SARS-CoV-2, the binding activity did not compete with S1B to the ACE2 receptor. This seems to indicate that 47D11 neutralizes SARS-CoV-1 and SARS-CoV-2 through a yet unknown mechanism different from binding interference ([@bib0625]). This study shows how, despite the high capability of the virus to mutate, targeting conserved core structure of the S1B receptor is a good strategy. This provides evidence for the design of the SARS-CoV-2 vaccine composed of viral structural proteins.

Another possible choice is Ivermectin, which showed to inhibit viral replication of SARS-CoV-2 in vitro ([@bib0050]), but in vivo studies need to evaluate its effect, clinical trials in COVID-19 are ongoing (NCT04390022, Phase 2).

The use of immunosuppressants like corticosteroids is quite controversial, for some it may be reasonable to counteract the effect of the cytokine storm induced by SARS-CoV-2. Although the recent open label study from Wu and colleagues showed a benefit for corticosteroids ([@bib0650]), clinical evidence did not support indistinct use of corticosteroids for SARS-CoV-1 lung injury, as many stated it could result in delayed viral clearance ([@bib0510]). Nevertheless, the most promising corticosteroid in SARS-CoV-2 infection is dexamethasone ([@bib0480]). Dexamethasone is showing to reduce mortality rates and efficacy especially in critically ill patients (on ventilator support or requiring oxygen therapy). This study enrolled 2104 patients who received a dose of 6 mg per day for 10 days compared to standard of care in 4321 patients. The risk of death was reduced by one-third in the dexamethasone arm in ventilated patients (NCT04381936, Phase 2/3). This evidence suggests we need reconsidering the role of corticosteroid treatment in the SARS-CoV-2 infection.

[Table 2](#tbl0010){ref-type="table"} summarizes other therapeutic options that have been discussed here ([Table 2](#tbl0010){ref-type="table"}).Table 2Summarizes other possible therapeutic compounds in SARS-CoV-2 infection.Table 2DrugMechanism of actionTrial/PhaseRecombinant form of the ACE2 ([@bib0310])Inhibition of viral adhesion to host cellsCamostat mesylate ([@bib0300]; [@bib0120])Inhibition of viral entry by inhibition of TMPRSS2NCT04321096 Phase1/2Favipiravir ([@bib0120]; [@bib0175])RNA-dependent RNA polymerase inhibitionNCT04358549, Phase 2Eculizumab ([@bib0250]; [@bib0120])C5 complement inhibitorNCT04288713Neutralizing Antibodies (47D11) ([@bib0625])Interaction with Spike proteinIvermectin ([@bib0050]; [@bib0120])Inhibition of in vitro replicationNCT04390022, Phase 2Corticosteroids: Methylprednisolone ([@bib0510]; [@bib0650]), Dexamethasone ([@bib0480])ImmunosuppressionNCT04273321, NCT04381936 Phase 2/3

In conclusions the author showed a list of possible therapies, many are being tested in clinical trials, some still need more testing. This review aimed to give an update on currently available therapies, already known drugs discussed here could have the advantage of speeding up the clinical trial process, since we already known their side effects and tolerability.
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